Vitamin D Status & Latitude Predict Brain Lesions in Adrenoleukodystrophy

Keith van Haren, MD^{1*}, Jacob Wilkes BS,² Ann B. Moser BA³, Gerald V. Raymond MD^{4,5}, Troy Richardson PhD⁶, Patrick Aubourg MD^{7,8}, Timothy W. Collins, PhD⁹, Ellen M Mowry MD, MPH⁴, and Joshua L. Bonkowsky, MD, PhD¹⁰⁻¹²

¹Division of Child Neurology, Department of Neurology, Stanford University, Palo Alto, California

²Intermountain Healthcare, Salt Lake City, Utah

³Peroxisomal Disease Laboratory, Kennedy Krieger Institute, Baltimore, Maryland

⁴Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland

⁵Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

⁶Children's Hospital Association, Lenexa, KS

⁷Department of Pediatric Neurology, APHP, Bicêtre University Hospital, Le Kremlin-Bicêtre, France.

⁸Paris-Sud University, INSERM U 1169, Le Kremlin-Bicêtre, France.

⁹Department of Geography, University of Utah, Salt Lake City, Utah

¹⁰Division of Pediatric Neurology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah

¹¹Brain and Spine Center, Primary Children's Hospital, Salt Lake City, Utah

¹²Primary Children's Center for Personalized Medicine, Salt Lake City, Utah

Running title: Vitamin D & Latitude Predict ALD Brain Lesions

Word Count Abstract: 100

Word Count Manuscript: 1265

Character count title: 73 (w spaces)

Character count running title: 46 (w spaces)

Number of references: 17

Number of figures: 1

Number of tables: 2

Supplemental tables: 1

Corresponding Author:

Keith van Haren

Department of Neurology, Stanford University School of Medicine

750 Welch Rd, Ste 317

Palo Alto, California

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Disclosures: All authors have completed the ICMJE uniform disclosure form and declare that the study described in the submitted work was supported, in part, by the Child Neurology Foundation Scientific Award and NIH/NINDS K23NS087151; KV has received research grants from Bluebird bio and Minoryx for clinical trials in ALD participants, separate from the submitted work; consulting fees from Bluebird bio, Minoryx, Viking Therapeutics, Poxel, and Orpheris for ALD therapy development separate from the submitted work. He participates in advisory boards for Poxel (paid), Viking (paid), ALD Connect (unpaid), and the United Leukodystrophy Foundations (unpaid). GVR has received consulting fees from Bluebird bio, Viking Therapeutics, and Minoryx for therapy development outside the submitted work. JLB has received research support from Sanofi and Autobahn as well as consulting fees from Neurogene, Passage Bio, Takeda, and Autobahn all for work outside the submitted work. He is an unpaid board member at ALD Connect and wFluidx. No other relationships or activities that could appear to have influenced the submitted work.

ABSTRACT

A subset of boys with X-linked adrenoleukodystrophy (ALD) develop inflammatory demyelinating brain lesions. Risk factors are largely undefined. We used two independent cohorts to assess whether low vitamin D status predicts lesion development. In our first cohort, we measured 25-hydroxyvitamin D in 53 plasma samples from 20 pre-lesional ALD boys followed at two centers; half subsequently developed lesions. In our second cohort, we measured latitude (using home ZIP code) among 230 ALD boys in a database of 51 US pediatric hospitals; over half developed lesions. In regression models, low plasma vitamin D and northerly latitudes independently predicted ALD brain lesions.

INTRODUCTION

X-linked adrenoleukodystrophy (ALD) is caused by mutations in a single gene (*ABCD1*) which encodes a peroxisomal fatty acid co-transporter, leading to accumulation of very long chain fatty acids in adrenal cortex, blood, and brain tissue.¹ Thirty to forty percent of boys with ALD will develop a disease state termed cerebral ALD (cALD); incidence is concentrated in the first decade.^{2,3} cALD is marked by progressive inflammatory demyelinating brain lesions. Left untreated cALD culminates in a vegetative state and death within a few years of onset.⁴ Small, early-stage brain lesions can be halted with hematopoietic stem cell transplant.^{4,5} Although the presence of a pathogenic *ABCD1* variant confirms an ALD diagnosis, the risk for cALD is discordant in siblings or even identical twins.¹ This suggests a role for environmental or epigenetic risk factors. Understanding etiology would be valuable for surveillance, treatment, and prevention.

Notably, ALD brain lesions share key similarities with multiple sclerosis lesions, including a predilection for the corpus callosum and an inflammatory demyelinating histology characterized by a leading edge of activated microglia, lipid-laden macrophages, and trailing lymphocytes.⁶ We reasoned that shared histology could suggest shared risk factors. Lower levels of vitamin D exposure have been robustly linked to higher risk of multiple sclerosis diagnosis, subsequent brain lesions, and improved prognosis.⁷⁻¹¹ Trials of vitamin D supplementation in multiple sclerosis have demonstrated modest benefits, including a reduction in the appearance of new brain lesions.^{12,13} Building on this premise, we investigated whether two established proxies for vitamin D exposure, plasma 25-hydroxyvitamin D status and north-south latitude, were correlated with the risk of developing cALD brain lesions.

METHODS

The Institutional Review Boards (IRB) of Stanford University, Kennedy Krieger Institute, Institut National de la Santé et de la Recherche Médicale (INSERM), and the University of Utah, exempted this study as non-human research.

To assess correlation of pre-morbid plasma 25-hydroxyvitamin D and subsequent development of cALD, we analyzed previously biobanked plasma samples collected as part of longitudinal clinical cohort studies of ALD boys at two centers (Kennedy Krieger Institute, Baltimore, Maryland, USA & INSERM, Paris, France) between May 1, 1999 and November 8, 2012. All patients were followed with serial MRIs every 6-12 months to screen for brain lesions according to standard care guidelines.¹ ALD brain lesions were defined as any gadolinium-enhancing white matter lesion on brain MRI. Plasma samples were collected longitudinally and stored at -80°C. Inclusion criteria for plasma analysis were: (i) molecular/biochemical diagnosis of ALD, (ii) male sex, (iii) age <11 years at sample collection (corresponding with period of maximal risk for cALD^{2,3}), (iv) normal brain MRI prior to plasma collection, and (v) availability of plasma samples from at least two timepoints prior to study endpoint. Study endpoints were (i) identification of cALD brain lesion on MRI or (ii) no ALD brain lesion identified at time of last follow-up. We excluded samples collected after a brain lesion was identified. We measured 25-hydroxyvitamin D levels (Heartland Assays, Inc.) and C26:0 lipid levels (Kennedy Krieger Institute) using tandem mass spectrometry. Lipid levels were measured at the time of plasma collection. We used a two-tailed Mann-Whitney U-test to assess differences between groups (Prism Graphpad v8.4). We used a logistic regression analysis to estimate the odds of developing brain lesion based on each patient's average 25-hydroxyvitamin D level (STATA v11).

To assess correlation of latitude and cALD, we determined the total number of ALD boys in the Pediatric Health Information System (PHIS) database. Patients had to be male, age <19 years, with a valid US ZIP code, and presenting between October 1, 2015 and June 30, 2019; with an ICD10 code for ALD, including E71520 - Childhood cerebral X-linked adrenoleukodystrophy; E71521 - Adolescent X-linked adrenoleukodystrophy; E71522 – Adrenomyeloneuropathy; E71528 - X-linked

adrenoleukodystrophy NEC; and E71529 - X-linked adrenoleukodystrophy NOS. We assessed for the primary clinical outcome, the development of brain lesions, by the presence of an ICD9 or ICD10 code for at least one of the following categories indicating CNS involvement: bone marrow transplant/hematopoietic stem cell transplant; cerebral degeneration or neurological dysfunction; or cortical visual loss/blindness (full list in **Supplemental Table 1**). We used ZIP code to determine latitude; we collapsed latitude into 2° ranges to allow a minimum of two ALD cases in each category. We excluded latitude ranges that had no ALD cases (19-24° north and >49° north). For each latitude range, we calculated the unadjusted probability of cALD among total ALD cases. We used a logistic regression model to calculate the probability of cALD among ALD patients adjusting for the size of PHIS population. Finally, we modeled the relationship between latitude ranges and probability of cALD compared to ALD using logistic regression, adjusting for total PHIS population size in that latitude (SAS v9.4).

RESULTS

We identified 20 ALD boys with plasma samples collected at 53 timepoints over an average of 3.8 ± 3.1 years between first plasma collection and clinical endpoint. Ten boys developed brain lesions during observation (median Loes score 1.0). Although plasma samples were collected at similar ages in both groups, patients who never developed cALD were followed longer (**Table 1**). Average 25-hydroxyvitamin D levels were significantly lower among boys who developed cALD than those who did not (median 28.9 vs 36.6 ng/ml); $p=0.019$ (**Table 1**). For each 10ng/mL decrease in 25-hydroxyvitamin D level, the odds ratio for developing cALD was 6.94 (95% confidence interval, 1.05, 45.8); $p=0.044$. Fatty acid biomarkers associated with ALD were available for 16 patients; they were similar across groups (**Table 1**).

For latitude analysis, we identified 230 ALD boys across 28 states and 21° of latitude; 57% of boys (n=132) developed cALD. Each 2° increase in latitude conferred an odds ratio of 1.17 (95% confidence interval, 1.01, 1.35); $p=0.036$ for developing cALD (**Table 2; Figure 1**).

DISCUSSION

Using independent cohorts, we found that ALD boys with lower pre-morbid plasma levels of 25-hydroxyvitamin D, or more northerly latitude of residence, were more likely to develop inflammatory brain lesions (cALD). These findings offer complementary lines of evidence implicating vitamin D and/or ultraviolet light exposure as a regulator of cALD risk.

We derived the concept of vitamin D as risk factor for cALD based on histologic similarities between ALD and multiple sclerosis brain lesions.^{6,14} In multiple sclerosis, vitamin D's therapeutic mechanism is attributed to its role in immune homeostasis.^{12,14} Similar immunologic mechanisms are plausible in reducing risk of developing the inflammatory demyelination that similarly characterizes cALD. However, because the ALD genotype disrupts peroxisomal fatty acid metabolism and causes elevated very long chain fatty acid levels, our findings may implicate vitamin D in mediating fatty acid metabolism and/or its role in immunologic homeostasis.¹⁵⁻¹⁷

Limitations of our study include the retrospective nature of our analyses and modest sample sizes, the latter of which limits our ability to assess for putative confounders. Although these analyses represent, to our knowledge, the first two assessments of vitamin D as a risk factor for cALD, prospective studies with or without intervention would further validate and refine the magnitude of risk associated with low vitamin D status in boys with an ALD genotype.

The advent of universal newborn screening for ALD has increased the number of ALD boys who can benefit from prospective MRI surveillance. Because ALD brain lesions rarely manifest before 2 years of age, widespread newborn screening could facilitate a trial of early life vitamin D supplementation to test its potential as a preventive therapy against ALD brain lesions.

In summary, we describe two complementary lines of evidence implicating low vitamin D status as a risk factor for the development of brain lesions among ALD boys. Our findings also support the possibility of shared disease mechanisms in cALD and multiple sclerosis.

ACKNOWLEDGEMENTS

JLB was supported by NIH grant 3UL1TR002538, and by the Bray Presidential Chair in Child Neurology research.

KV was supported by Child Neurology Society Scientific Award; NIH grant K23NS087151; the Tashia and John Morgridge Endowed Faculty Scholarship in Pediatric Translational Medicine of the Stanford Maternal & Child Health Research Institute; gifts to the Lucile Packard Foundation, the Lenail-Yoler Family, the Adler Family, the Senkut Family, and from Arrivederci ALD.

AUTHOR CONTRIBUTIONS

KV and JLB conceptualized and designed the study and drafted the manuscript.

JLB, EMM, KV, TWC, JW analyzed the data and edited the manuscript for intellectual content.

AM, GVR, and PA supervised and curated the longitudinal cohorts including specimen management, specimen selection, and associated clinical data.

POTENTIAL CONFLICTS OF INTEREST

Keith Van Haren: Dr Van Haren is conducting an NIH/NINDS funded (K23NS087151) pilot study of over-the-counter vitamin D supplementation in boys with adrenoleukodystrophy (NCT02595489)

Jacob Wilkes: Nothing to report.

Ann B. Moser: Nothing to report.

Gerald V. Raymond: Nothing to report.

Troy Richardson: Nothing to report.

Patrick Aubourg: Nothing to report.

Timothy Collins: Nothing to report.

Ellen M. Mowry: Nothing to report.

Joshua L. Bonkowsky: Nothing to report.

References:

1. Kemp S, Berger J, Aubourg P. X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects. *Biochim Biophys Acta*. 2012;1822(9):1465-1474.
2. Huffnagel IC, Laheji FK, Aziz-Bose R, et al. The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International Collaboration. *The Journal of clinical endocrinology and metabolism*. 2019;104(1):118-126.
3. Bezman L, Moser HW. Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes. *Am J Med Genet*. 1998;76(5):415-419.
4. Mahmood A, Raymond GV, Dubey P, Peters C, Moser HW. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. *Lancet Neurol*. 2007;6(8):687-692.
5. Peters C, Charnas LR, Tan Y, et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. *Blood*. 2004;104(3):881-888.
6. Pfeifenbring S, von Baumgarten L, Schuller U, et al. Biopsy findings of symptomatic cerebral X-linked adrenoleukodystrophy and histological differentiation from multiple sclerosis. *Neuropathology and applied neurobiology*. 2013.
7. Simpson S, Jr., Wang W, Otahal P, Blizzard L, van der Mei IAF, Taylor BV. Latitude continues to be significantly associated with the prevalence of multiple sclerosis: an updated meta-analysis. *J Neurol Neurosurg Psychiatry*. 2019;90(11):1193-1200.
8. Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. *Ann Neurol*. 2010;67(5):618-624.
9. Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. *Ann Neurol*. 2012;72(2):234-240.
10. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. *JAMA*. 2006;296(23):2832-2838.

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

11. Kurtzke JF. The distribution of multiple sclerosis and other diseases. *Acta Neurol Scand.* 1966;42(2):221-243.
12. Sotirchos ES, Bhargava P, Eckstein C, et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. *Neurology.* 2016;86(4):382-390.
13. McLaughlin L, Clarke L, Khalilidehkordi E, Butzkueven H, Taylor B, Broadley SA. Vitamin D for the treatment of multiple sclerosis: a meta-analysis. *J Neurol.* 2018;265(12):2893-2905.
14. Pierrot-Deseilligny C, Souberbielle JC. Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis. *Therapeutic advances in neurological disorders.* 2013;6(2):81-116.
15. Ji L, Gupta M, Feldman BJ. Vitamin D Regulates Fatty Acid Composition in Subcutaneous Adipose Tissue Through Elovl3. *Endocrinology.* 2016;157(1):91-97.
16. Lupton JR, Faridi KF, Martin SS, et al. Deficient serum 25-hydroxyvitamin D is associated with an atherogenic lipid profile: The Very Large Database of Lipids (VLDL-3) study. *J Clin Lipidol.* 2016;10(1):72-81 e71.
17. Nandi A, Wadhwani N, Joshi SR. Vitamin D deficiency influences fatty acid metabolism. *Prostaglandins Leukot Essent Fatty Acids.* 2019;140:57-63.

Table 1. Demographics and plasma levels from 20 ALD boys at two academic medical centers. All boys had normal brain MRIs at the start of observation and were followed with serial MRIs to detect early-stage cALD. Clinical endpoints assigned according to whether patient developed cALD during period of observation.

	Subsequent cALD		no cALD		<i>p</i>
	Median	Interquartile range	Median	Interquartile range	
Patients meeting clinical endpoint (total n=20)	10	n/a	10	n/a	n/a
Unique time points with plasma samples available prior to clinical endpoint (minimum 2 per patient)	21	n/a	32	n/a	n/a
Age at time of plasma sample, years	5.3	4.2 – 7.0	6.6	4.2 – 7.8	0.36
Age at endpoint, years	6.7	5.5 – 7.7	8.4	7.8 – 10.4	0.02
Duration of observation from first plasma sample to endpoint, years	2.0	1.2 – 2.3	5.2	3.4 – 5.9	0.007
MRI lesion score (Loes score) at time of last MRI (scale 0 – 34)	1	1 – 1.8	0	0	n/a
C26:0, (n=8 patients with 18 plasma samples), ug/ml	1.0	0.5 – 1.1	0.6	0.4 – 1.0	0.30
C26:0-lysophosphatidylcholine, (n=8 patients with 18 plasma samples), ug/ml	0.3	0.2 – 0.4	0.3	0.2 – 0.3	0.48
Plasma 25-hydroxyvitamin D, all timepoints (n=53), ng/ml	27.5	23.4 – 31.9	33.8	29.3 – 42.8	0.007
Plasma 25-hydroxyvitamin D, each patient's timepoints averaged to a single value (n=20), ng/ml	28.9	25.9 – 32.6	36.6	33.1 – 42.0	0.019

Table 2: Incidence risk of cALD and latitude. cALD rates at each latitude range are shown before and after adjustments for Pediatric Healthy Information System (PHIS) population. The inclusion of latitude in the regression model significantly affected cALD rates. To protect patient confidentiality, we have not provided numerators (cALD patients) and denominators (all ALD patients) by latitude category since almost half the latitude ranges have either (i) fewer than 10 patients or (ii) fewer than 3 hospitals.

Degrees Latitude*	Total PHIS Population	Unadjusted probability of cALD (% with cALD)	Adjusted** probability of cALD – latitude excluded from model (% with cALD)	Adjusted** probability of cALD – latitude included in model (% with cALD)
25°-26°	101,841	50.0%	54.7%	36.7%
27°-28°	106,949	25.0%	54.8%	40.2%
29°-30°	323,873	30.0%	55.4%	42.8%
31°-32°	438,066	50.0%	55.5%	46.4%
33°-34°	881,280	40.0%	56.6%	48.2%
35°-36°	472,796	43.8%	55.6%	53.9%
37°-38°	437,657	75.8%	55.5%	58.0%
39°-40°	1,060,064	56.0%	57.2%	58.5%
41°-42°	698,861	72.1%	56.1%	64.2%
43°-44°	156,815	50.0%	54.8%	69.9%
45°-46°	51,321	0.0%	54.6%	73.4%
47°-48°	72,553	60.0%	54.6%	76.3%

*Collapsed to get at least 2 cases of ALD in each category

**Adjusted for PHIS population

Figure 1. Graph of incidence risk of an ALD brain lesion compared to latitude. Each 2° increase in latitude conferred an odds ratio of 1.17 (95% confidence interval 1.01, 1.35); $p=0.036$ for developing cALD.

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Supplemental Table 1. List of ICD10 codes used to determine presence of cALD.

Code Type	Code	Description	cALD Grouping
ICD-9-PCS-CD	4100	BONE MARROW TRANSPL NOS	Transplant
ICD-9-PCS-CD	4103	ALLO MARROW TRANSPL NEC	Transplant
ICD-9-PCS-CD	4104	AUTO STEM CELL TRANSPLAN	Transplant
ICD-9-PCS-CD	4105	ALLOGENIC STEM CELL TRAN	Transplant
ICD-9-PCS-CD	4106	CORD BLD STEM CELL TNSPL	Transplant
ICD-9-CM-CD	99685	COMP MARROW TRANSPLANT	Transplant
ICD-9-CM-CD	99688	COMP STEM CELL TRANSPL	Transplant
ICD-9-CM-CD	V4281	HX BONE MARROW TRANSPLNT	Transplant
ICD-9-CM-CD	V4282	HX PERIPH STEM CELL TRNS	Transplant
ICD-10-PCS-CD	30233Y0	TRANSFUSION AUTOLOG HSC INTO PERIPH VEIN, PERQ	Transplant
ICD-10-PCS-CD	30233Y1	TRANSFUSION NONAUT HSC INTO PERIPH VEIN, PERQ	Transplant
ICD-10-PCS-CD	30233Y2	TRANSFUS ALLOGEN REL HSC INTO PERIPH VEIN, PERQ	Transplant
ICD-10-PCS-CD	30243G1	TRANSFUS NONAUT BONE MARROW CENTRAL VEIN, PERQ	Transplant
ICD-10-PCS-CD	30243G2	TRANSFUS ALLOGEN RELATED BM CENTRAL VEIN, PERQ	Transplant
ICD-10-PCS-CD	30243G3	TRANSFUS ALLOGEN UNRELATED BM CENTRAL VEIN, PERQ	Transplant
ICD-10-PCS-CD	30243Y0	TRANSFUSION AUTOLOG HSC INTO CENTRAL VEIN, PERQ	Transplant
ICD-10-PCS-CD	30243Y1	TRANSFUSION NONAUT HSC INTO CENTRAL VEIN, PERQ	Transplant
ICD-10-PCS-CD	30243Y2	TRANSFUS ALLOGEN REL HSC INTO CENTRAL VEIN, PERQ	Transplant
ICD-10-PCS-CD	30243Y3	TRANSFUS ALLOGEN UNREL HSC IN CENTRAL VEIN, PERQ	Transplant
ICD-10-CM-CD	T8600	COMPLICATION BONE MARROW TRANSPLANT NOS	Transplant
ICD-10-CM-CD	T8600	COMPLICATION BONE MARROW TRANSPLANT NOS	Transplant
ICD-10-CM-CD	T8601	BONE MARROW TRANSPLANT REJECTION	Transplant
ICD-10-CM-CD	T8601	BONE MARROW TRANSPLANT REJECTION	Transplant
ICD-10-CM-CD	T8602	BONE MARROW TRANSPLANT FAILURE	Transplant
ICD-10-CM-CD	T8602	BONE MARROW TRANSPLANT FAILURE	Transplant
ICD-10-CM-CD	T8609	COMPLICATIONS BONE MARROW TRANSPLANT NEC	Transplant
ICD-10-CM-CD	T8609	COMPLICATIONS BONE MARROW TRANSPLANT NEC	Transplant
ICD-10-CM-CD	Z48290	ENCOUNTER AFTERCARE FOLLOW BONE MARROW TRANSPL	Transplant
ICD-10-CM-CD	Z9481	BONE MARROW TRANSPLANT STATUS	Transplant
ICD-10-CM-CD	Z9484	STEM CELLS TRANSPLANT STATUS	Transplant
ICD-9-CM-CD	3317	CEREBRAL DEGEN IN DCE	Cerebral degeneration
ICD-10-CM-CD	G3189	DEGENERATIVE DISEASES NERVOUS SYSTEM NEC	Cerebral degeneration
ICD-10-CM-CD	G319	DEGENERATIVE DISEASE NERVOUS SYSTEM NOS	Cerebral degeneration
ICD-9-CM-CD	3670	HYPERMETROPIA	Blindness, vision loss
ICD-9-CM-CD	3671	MYOPIA	Blindness, vision loss
ICD-9-CM-CD	3693	BLINDNESS NOS BOTH EYES	Blindness, vision loss
ICD-9-CM-CD	3694	LEGAL BLINDNESS USA DEF	Blindness, vision loss
ICD-9-CM-CD	3698	VISUAL LOSS ONE EYE NOS	Blindness, vision loss
ICD-9-CM-CD	3699	VISUAL LOSS NOS	Blindness, vision loss
ICD-9-CM-CD	36720	ASTIGMATISM NOS	Blindness, vision loss
ICD-9-CM-CD	36900	BOTH EYES BLIND WHO DEF	Blindness, vision loss
ICD-9-CM-CD	36922	SEVERE IMPAIR BOTH EYES	Blindness, vision loss
ICD-9-CM-CD	36960	BLINDNESS ONE EYE	Blindness, vision loss
ICD-10-CM-CD	H5202	HYPERMETROPIA LEFT EYE	Blindness, vision loss
ICD-10-CM-CD	H5203	HYPERMETROPIA BILATERAL	Blindness, vision loss
ICD-10-CM-CD	H5213	MYOPIA BILATERAL	Blindness, vision loss

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

ICD-10-CM-CD	H52202	ASTIGMATISM NOS LEFT EYE	Blindness, vision loss
ICD-10-CM-CD	H52203	ASTIGMATISM NOS BILATERAL	Blindness, vision loss
ICD-10-CM-CD	H52209	ASTIGMATISM NOS EYE NOS	Blindness, vision loss
ICD-10-CM-CD	H52223	REGULAR ASTIGMATISM BILATERAL	Blindness, vision loss
ICD-10-CM-CD	H527	DISORDER REFRACTION NOS	Blindness, vision loss
ICD-10-CM-CD	H540	BLINDNESS BOTH EYES	Blindness, vision loss
ICD-10-CM-CD	H543	UNQUALIFIED VISUAL LOSS BOTH EYES	Blindness, vision loss
ICD-10-CM-CD	H547	VISUAL LOSS NOS	Blindness, vision loss
ICD-10-CM-CD	H548	LEGAL BLINDNESS AS DEFINED IN USA	Blindness, vision loss
ICD-9-CM-CD	3682	DIPLOPIA	Eye disorders
ICD-9-CM-CD	3688	VISUAL DISTURBANCES NEC	Eye disorders
ICD-9-CM-CD	3689	VISUAL DISTURBANCE NOS	Eye disorders
ICD-9-CM-CD	3789	EYE MOVEMENT DISORD NOS	Eye disorders
ICD-9-CM-CD	3798	OTHER EYE DISORDERS	Eye disorders
ICD-9-CM-CD	36731	ANISOMETROPIA	Eye disorders
ICD-9-CM-CD	36751	ACCOMMODATION PARESIS	Eye disorders
ICD-9-CM-CD	36803	REFRACTIVE AMBLYOPIA	Eye disorders
ICD-9-CM-CD	36813	VISUAL DISCOMFORT	Eye disorders
ICD-9-CM-CD	36816	PSYCHOPHYSIC VIS DISTURB	Eye disorders
ICD-9-CM-CD	37430	EYELID PTOSIS NOS	Eye disorders
ICD-9-CM-CD	37489	EYELID DISORDER NEC	Eye disorders
ICD-9-CM-CD	37710	OPTIC ATROPHY NOS	Eye disorders
ICD-9-CM-CD	37775	CORTICAL BLINDNESS	Eye disorders
ICD-9-CM-CD	37800	ESOTROPIA NOS	Eye disorders
ICD-9-CM-CD	37810	EXOTROPIA NOS	Eye disorders
ICD-9-CM-CD	37811	MONOCULAR EXOTROPIA	Eye disorders
ICD-9-CM-CD	37815	ALTERNATING EXOTROPIA	Eye disorders
ICD-9-CM-CD	37854	SIXTH NERVE PALSY	Eye disorders
ICD-9-CM-CD	37887	SKEW DEVIATION EYE	Eye disorders
ICD-9-CM-CD	37950	NYSTAGMUS NOS	Eye disorders
ICD-9-CM-CD	37956	NYSTAGMUS NEC	Eye disorders
ICD-9-CM-CD	37992	EYE SWELLING OR MASS	Eye disorders
ICD-10-CM-CD	H02402	PTOSIS EYELID NOS LEFT EYELID	Eye disorders
ICD-10-CM-CD	H0259	DISORDERS AFFECTING EYELID FUNCTION NEC	Eye disorders
ICD-10-CM-CD	H4710	PAPILLEDEMA NOS	Eye disorders
ICD-10-CM-CD	H4720	OPTIC ATROPHY NOS	Eye disorders
ICD-10-CM-CD	H47293	OPTIC ATROPHY NEC BILATERAL	Eye disorders
ICD-10-CM-CD	H47611	CORTICAL BLINDNESS RIGHT SIDE BRAIN	Eye disorders
ICD-10-CM-CD	H47612	CORTICAL BLINDNESS LEFT SIDE BRAIN	Eye disorders
ICD-10-CM-CD	H47619	CORTICAL BLINDNESS BRAIN SIDE NOS	Eye disorders
ICD-10-CM-CD	H5000	ESOTROPIA NOS	Eye disorders
ICD-10-CM-CD	H5005	ALTERNATING ESOTROPIA	Eye disorders
ICD-10-CM-CD	H5010	EXOTROPIA NOS	Eye disorders
ICD-10-CM-CD	H50112	MONOCULAR EXOTROPIA LEFT EYE	Eye disorders
ICD-10-CM-CD	H5015	ALTERNATING EXOTROPIA	Eye disorders
ICD-10-CM-CD	H50332	INTERMITTENT MONOCULAR EXOTROPIA LEFT EYE	Eye disorders
ICD-10-CM-CD	H5043	ACCOMMODATIVE COMPONENT IN ESOTROPIA	Eye disorders
ICD-10-CM-CD	H509	UNSPECIFIED STRABISMUS	Eye disorders
ICD-10-CM-CD	H518	OTHER SPECIFIED DISORDERS OF BINOCULAR MOVEMENT	Eye disorders

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

ICD-10-CM-CD	H53002	UNSPECIFIED AMBLYOPIA, LEFT EYE	Eye disorders
ICD-10-CM-CD	H53003	UNSPECIFIED AMBLYOPIA, BILATERAL	Eye disorders
ICD-10-CM-CD	H53009	UNSPECIFIED AMBLYOPIA, UNSPECIFIED EYE	Eye disorders
ICD-10-CM-CD	H53149	VISUAL DISCOMFORT, UNSPECIFIED	Eye disorders
ICD-10-CM-CD	H532	DIPLOPIA	Eye disorders
ICD-10-CM-CD	H538	VISUAL DISTURBANCES NEC	Eye disorders
ICD-10-CM-CD	H539	VISUAL DISTURBANCE NOS	Eye disorders
ICD-10-CM-CD	H5500	NYSTAGMUS NOS	Eye disorders
ICD-10-CM-CD	H5501	CONGENITAL NYSTAGMUS	Eye disorders
ICD-10-CM-CD	H5509	OTHER FORMS NYSTAGMUS	Eye disorders
ICD-10-CM-CD	H5702	ANISOCORIA	Eye disorders
ICD-10-CM-CD	H5704	MYDRIASIS	Eye disorders
ICD-10-CM-CD	H5711	OCULAR PAIN RIGHT EYE	Eye disorders
ICD-10-CM-CD	H578	SPECIFIED DISORDERS EYE & ADNEXA NEC	Eye disorders
ICD-10-CM-CD	H579	DISORDER EYE & ADNEXA NOS	Eye disorders
ICD-10-CM-CD	R441	VISUAL HALLUCINATIONS	Eye disorders
ICD-9-CM-CD	7801	HALLUCINATIONS	Neurologic disorders
ICD-9-CM-CD	7843	APHASIA	Neurologic disorders
ICD-9-CM-CD	7845	SPEECH DISTURBANCE NEC	Neurologic disorders
ICD-9-CM-CD	33183	MILD COGN IMPAIRMENT	Neurologic disorders
ICD-9-CM-CD	78002	TRANS ALTER AWARENESS	Neurologic disorders
ICD-9-CM-CD	78093	MEMORY LOSS	Neurologic disorders
ICD-9-CM-CD	78097	ALTERED MENTAL STATUS	Neurologic disorders
ICD-9-CM-CD	78451	DYSARTHRIA	Neurologic disorders
ICD-9-CM-CD	78459	SPEECH DISTURBANCE NEC	Neurologic disorders
ICD-9-CM-CD	78469	SYMBOLIC DYSFUNCTION NEC	Neurologic disorders
ICD-9-CM-CD	79955	FL & EXEC FUNCT DEFICIT	Neurologic disorders
ICD-10-CM-CD	G3184	MILD COGNITIVE IMPAIRMENT SO STATED	Neurologic disorders
ICD-10-CM-CD	R404	TRANSIENT ALTERATION AWARENESS	Neurologic disorders
ICD-10-CM-CD	R410	DISORIENTATION NOS	Neurologic disorders
ICD-10-CM-CD	R4182	ALTERED MENTAL STATUS NOS	Neurologic disorders
ICD-10-CM-CD	R41843	PSYCHOMOTOR DEFICIT	Neurologic disorders
ICD-10-CM-CD	R41844	FRONTAL LOBE & EXECUTIVE FUNCTION DEFICIT	Neurologic disorders
ICD-10-CM-CD	R4189	SX & SIGN INVOLV COGNITIVE FUNC & AWARENESS NEC	Neurologic disorders
ICD-10-CM-CD	R440	AUDITORY HALLUCINATIONS	Neurologic disorders
ICD-10-CM-CD	R443	HALLUCINATIONS NOS	Neurologic disorders
ICD-10-CM-CD	R4701	APHASIA	Neurologic disorders
ICD-10-CM-CD	R4702	DYSPHASIA	Neurologic disorders
ICD-10-CM-CD	R471	DYSARTHRIA & ANARTHRIA	Neurologic disorders
ICD-10-CM-CD	R479	SPEECH DISTURBANCES NOS	Neurologic disorders
ICD-10-CM-CD	R488	SYMBOLIC DYSFUNCTIONS NEC	Neurologic disorders